Clinical Trials

170 enrolled

Other solid neoplasm

Solid Tumors

NCT06792695 2026-05-11

CANTOR

120 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04322318 2026-05-05

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

256 enrolled

Genitourinary

Wilms Tumor

NCT06941857 2026-05-05

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

20 enrolled

Carcinoma, Pancreatic Neoplasms

NCT06846346 2026-04-28

GRACIE

88 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT07328425 2026-04-03

ISG-TULIPS

20 enrolled

Desmoplastic Small Round Cell Tumor

NCT05999994 2026-03-27

CAMPFIRE

105 enrolled

Tumor-Agnostic

Neoplasms

NCT06450041 2026-03-23

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

62 enrolled

Neuroblastoma

NCT05806931 2026-03-18

SCOTI

50 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT07011576 2026-03-18

FRUITFUL

60 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT01356290 2026-02-23

MEMMAT

232 enrolled

Ependymoma, Medulloblastoma, Recurrence

NCT05669339 2026-02-18

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

12 enrolled

Carcinoma, Hepatocellular

NCT06219941 2026-02-12

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

224 enrolled

Biliary Tract Neoplasms, Stomach Neoplasms

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

45 enrolled

Neuroblastoma

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT03977233 2026-01-13

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

45 enrolled

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT03322995 2026-01-08

PANC

125 enrolled

Pancreatic Neoplasms

NCT07309185 2025-12-30

Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy

66 enrolled

Stomach Neoplasms

NCT05959356 2025-12-17

CEIL

198 enrolled

Colorectal Neoplasms

NCT06714357 2025-12-17

VICTORIA

130 enrolled

Colorectal Neoplasms

NCT04753879 2025-12-04

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

38 enrolled

Pancreatic Neoplasms

NCT04205968 2025-11-05

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

94 enrolled

Metastatic Small Intestinal Adenocarcinoma

NCT07150247 2025-09-26

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

20 enrolled

BRAF V600 Colorectal Cancer

NCT05571644 2025-07-23

OPTICAL-2

143 enrolled

Colorectal Neoplasms

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

120 enrolled

Neuroblastoma

NCT05727163 2025-05-30

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

194 enrolled

Colorectal Cancer Metastatic

NCT03401294 2025-05-09

CONVERSION

32 enrolled

Colorectal Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT05859750 2024-12-16

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

78 enrolled

Pancreatic Neoplasms

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT06547203 2024-08-09

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

34 enrolled

Colorectal Neoplasms

NCT05462236 2024-07-09

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

120 enrolled

Colorectal Neoplasms

NCT05229003 2024-07-03

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

44 enrolled

Colorectal Neoplasms

NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

60 enrolled

Colorectal Neoplasms

NCT06242067 2024-02-05

BEV-TASIRI

50 enrolled

Colorectal Neoplasms

NCT05962502 2023-08-31

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

54 enrolled